Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease

Women with inflammatory bowel disease (IBD) are at increased risk of high‐grade cervical intraepithelial neoplasia and cervical cancer (CIN2+).

[1]  N. Houwing,et al.  Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review , 2022, Preventive medicine reports.

[2]  I. D. de Kok,et al.  Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study , 2021, Journal of Crohn's & colitis.

[3]  Jackson R. Richards,et al.  Genetic polymorphisms in tumor necrosis factor alpha and interleukin‐10 are associated with an increased risk of cervical cancer , 2019, International immunopharmacology.

[4]  J. Sanderson,et al.  Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives , 2018, Journal of Crohn's & colitis.

[5]  C. Mulder,et al.  Neoplasia and Precursor Lesions of the Female Genital Tract in IBD: Epidemiology, Role of Immunosuppressants, and Clinical Implications. , 2018, Inflammatory bowel diseases.

[6]  D. Hommes,et al.  Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease , 2017, BMJ Open.

[7]  A. V. van Bodegraven,et al.  Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy , 2016, Molecular Diagnosis & Therapy.

[8]  P. Sparén,et al.  Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden , 2016, Annals of the rheumatic diseases.

[9]  S. Kane,et al.  Monitoring for Extra-Intestinal Cancers in IBD , 2015, Current Gastroenterology Reports.

[10]  A. Moscicki,et al.  Expression of nucleic acid‐sensing Toll‐like receptors predicts HPV16 clearance associated with an E6‐directed cell‐mediated response , 2015, International journal of cancer.

[11]  M. Frisch,et al.  Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  E. Barnes,et al.  Are Patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at Increased Risk of Cervical High-grade Dysplasia/Cancer? A Meta-analysis , 2014, Inflammatory bowel diseases.

[13]  C. Meijer,et al.  Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions , 2014, Nature Reviews Cancer.

[14]  S. Hernández-Díaz,et al.  Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study , 2014, Annals of the rheumatic diseases.

[15]  E. Horváth-Puhó,et al.  Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study , 2013, The American Journal of Gastroenterology.

[16]  J. Berkhof,et al.  Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. , 2013, American journal of epidemiology.

[17]  A. Bousvaros,et al.  Immunogenicity and Tolerability to Human Papillomavirus-like Particle Vaccine in Girls and Young Women with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[18]  M. Plummer,et al.  Global burden of human papillomavirus and related diseases. , 2012, Vaccine.

[19]  M. Schiffman,et al.  Updating the natural history of human papillomavirus and anogenital cancers. , 2012, Vaccine.

[20]  Christopher F. Martin,et al.  Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. , 2012, Gastroenterology.

[21]  L. Beaugerie.  Inflammatory bowel disease therapies and cancer risk: where are we and where are we going? , 2011, Gut.

[22]  M. Stanley.  HPV - immune response to infection and vaccination , 2010, Infectious Agents and Cancer.

[23]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[24]  C. Porter,et al.  Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[26]  C. Lees,et al.  Lack of association between cervical dysplasia and IBD: A large case–control study , 2009, Inflammatory bowel diseases.

[27]  H. Arrighi,et al.  Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease , 2009, The American Journal of Gastroenterology.

[28]  P. Vacek,et al.  Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. , 2009, Cancer research.

[29]  J. Palefsky,et al.  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions , 2009, International journal of cancer.

[30]  E. Kliewer,et al.  Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. , 2009, Gastroenterology.

[31]  S. Hutfless,et al.  Screening differences and risk of cervical cancer in inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.

[32]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[33]  S. Kane,et al.  Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.

[34]  M. Casparie,et al.  Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and Archive , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[35]  S. Mannor,et al.  Abnormalities of uterine cervix in women with inflammatory bowel disease. , 2006, World journal of gastroenterology.

[36]  J. Doorbar,et al.  Molecular biology of human papillomavirus infection and cervical cancer. , 2006, Clinical science.

[37]  J. Palefsky.  Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy , 2003, Current opinion in oncology.

[38]  A. Moscicki,et al.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. , 2001, JAMA.

[39]  J. Lennard-jones,et al.  Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. , 1997, European journal of gastroenterology & hepatology.

[40]  E. A. Foster,et al.  A computer-assisted surgical pathology system. , 1982, American journal of clinical pathology.

[41]  P. Higgins,et al.  Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). , 2014, Journal of Crohn's & colitis.

[42]  T. Sasagawa,et al.  Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[43]  A. N. Goudswaard,et al.  [Summary of the practice guideline 'Prevention and early diagnosis of cervical cancer' of the Dutch College of General Practitioners]. , 2009, Nederlands tijdschrift voor geneeskunde.